Clinical trial
Alendronate and/or Parathyroid Hormone for Osteoporosis
NCT00000400 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00000400 |
|---|---|
| Title | Alendronate and/or Parathyroid Hormone for Osteoporosis |
| Official title | Bone Formation-Resorption Coupling and Osteoporosis |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Human parathyroid hormone [hPTH-(1-34)], alendronate |
| Enrollment | 176 |
| Start date | Aug 1, 1999 |
| Primary completion | Apr 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Nov 4, 1999 |
| Last update posted | Dec 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: